BookAnne C. Chiang, Roy S. Herbst, editors.
Summary: Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.
Contents:
Tumor Microenvironment: Immune Effector and Suppressor Imbalance
Biomarkers: is tumor mutational burden the new prognostic grail?
Liquid biopsies: new technology and evidence
Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance
What can we learn from acquired resistance?
Management of Brain Metastases
Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors
Therapeutic Advances in Small Cell Lung Cancer Management
Small Cell Lung Cancer: Biology Advances
Immunotherapy and Radiotherapy: New Strategies
Ultimate Precision: Targeting Cancer but not Normal Self-Replication
Index.